Triumvira Therapeutics

Vision

Triumvira’s mission is to focus on improving the lives of patients. Grounded by a deep understanding of immunology and expertise in drug development, our team is committed to identify, develop and commercialize innovative therapies that will empower a patient’s own immune system to tackle serious and life-threatening diseases.

Approach

Triumvira Immunologics, Inc. (“Triumvira”) is a clinical stage immunotherapy company with the vision of developing novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T-cell receptor (TCR) therapies. Their proprietary T-cell Antigen Coupler (TAC) technology recruits the entire natural T-cell receptor and functions independent of the Major Histocompatibility Complex (MHC), potentially allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer.

Triumvira Therapeutics is addressing

• Leap 04 / Prevent and cure cancer